CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) — LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $10.00 per share for aggregate gross proceeds of approximately $70.0 million. All of the shares are being offered by LogicBio. In addition, LogicBio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock from LogicBio at the initial public offering price, less the underwriting discounts and commissions. LogicBio’s common stock is expected to begin trading on The Nasdaq Global Market on October 19, 2018 under the ticker symbol “LOGC.” The offering is expected to close on October 23, 2018, subject to customary closing conditions.

Jefferies, Barclays and William Blair are acting as joint book-running managers for the proposed offering. Chardan is acting as the lead manager for the offering.

About LogicBio Therapeutics

LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Massachusetts, LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.